Loading…

Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy

Background: Ultraviolet light (UVL) upregulates HIV transcription in vitro and in transgenic mice. AIDS-associated psoriasis and pruritus respond to phototherapy. Objective: Our goal was to determine the effect of phototherapy on viral load and immunologic parameters in HIV-positive patients. Method...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 1999, Vol.40 (1), p.48-60
Main Authors: Breuer-McHam, Joan, Marshall, Gailen, Adu-Oppong, Ahmed, Goller, Michelle, Mays, Steven, Berger, Tim, Lewis, Dorothy E., Duvic, Madeleine
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Ultraviolet light (UVL) upregulates HIV transcription in vitro and in transgenic mice. AIDS-associated psoriasis and pruritus respond to phototherapy. Objective: Our goal was to determine the effect of phototherapy on viral load and immunologic parameters in HIV-positive patients. Methods: T cell subsets, p24, plasma cytokines, serum or plasma HIV-RNA, dosage, and antivirals were assessed in HIV-positive patients and negative controls receiving 6 weeks of phototherapy with UVB and in untreated controls. Results: Phototherapy improved skin conditions without significantly affecting T cell numbers. Plasma p24 increased 2-fold ( P = .055) and HIV-RNA levels 4-fold ( P = .022) 6 weeks from baseline in patients who entered the trial before March 1995. Later patients who were mostly receiving combination antiviral therapy showed a 4-fold reduction in serum HIV-RNA ( P = .012) at 2 weeks. The effect of UVB on viral load at 6 weeks was dependent on the baseline level ( P = .006). IL-10 increased and was inversely related to HIV-RNA levels ( P = .0267). Conclusion: Phototherapy is associated with HIV load alterations, depending on patients’ initial HIV-RNA, antiviral therapy, skin type, and UVL dosage. (J Am Acad Dermatol 1999;40:48-60.)
ISSN:0190-9622
1097-6787
DOI:10.1016/S0190-9622(99)70527-X